Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alphabet Inc.
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
The company’s AlphaFold platform impressed two years ago, and is now extending its machine learning tech into small-molecule drug discovery with big pharma partners.
Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.
Despite all of the buzz around adoption of digital health tools and whopping VC investments in consumer-facing digital health firms, pharma has yet to articulate a business model for co-development or integration of behavior-modifying digital therapeutics into their portfolios.
- Digital Health
- Other Names / Subsidiaries
- Google Life Sciences
- Verily Life Sciences LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.